HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David Fairlamb Selected Research

human TGFB3 protein

9/2011Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
9/2010Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds.
8/2009Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David Fairlamb Research Topics

Disease

2Cicatrix (Scar)
09/2011 - 08/2009
1Wounds and Injuries (Trauma)
09/2010
1Lung Neoplasms (Lung Cancer)
05/2005
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2005

Drug/Important Bio-Agent (IBA)

3human TGFB3 proteinIBA
09/2011 - 08/2009
1Transforming Growth Factor beta (TGF-beta)IBA
09/2011
1Transforming Growth Factors (Transforming Growth Factor)IBA
09/2010
1Transforming Growth Factor beta3 (TGF beta 3)IBA
08/2009
1Pharmaceutical PreparationsIBA
08/2009
1Cisplatin (Platino)FDA LinkGeneric
05/2005

Therapy/Procedure

1Therapeutics
09/2011
1Radiotherapy
05/2005
1Drug Therapy (Chemotherapy)
05/2005